Sterling Investment Advisors (Pennsylvania)’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.84M | Sell |
2,947
-175
| -6% | -$119K | 0.31% | 81 |
|
|
2026
Q1 | $2.41M | Sell |
3,122
-230
| -7% | -$176K | 0.44% | 66 |
|
|
2025
Q4 | $2.59M | Sell |
3,352
-65
| -2% | -$44.1K | 0.48% | 62 |
|
|
2025
Q3 | $1.92M | Sell |
3,417
-280
| -8% | -$158K | 0.37% | 71 |
|
|
2025
Q2 | $1.94M | Sell |
3,697
-15
| -0.4% | -$8.37K | 0.43% | 68 |
|
|
2025
Q1 | $2.35M | Sell |
3,712
-50
| -1% | -$34.4K | 0.57% | 55 |
|
|
2024
Q4 | $2.68M | Buy |
3,762
+715
| +23% | +$600K | 0.65% | 50 |
|
|
2024
Q3 | $3.2M | Sell |
3,047
-280
| -8% | -$312K | 0.81% | 41 |
|
|
2024
Q2 | $3.5M | Sell |
3,327
-25
| -0.7% | -$24.2K | 0.95% | 31 |
|
|
2024
Q1 | $3.23M | Sell |
3,352
-115
| -3% | -$109K | 0.91% | 37 |
|
|
2023
Q4 | $3.05M | Sell |
3,467
-70
| -2% | -$57.6K | 0.95% | 33 |
|
|
2023
Q3 | $2.91M | Hold |
3,537
| – | – | 1.02% | 33 |
|
|
2023
Q2 | $2.54M | Sell |
3,537
-215
| -6% | -$166K | 0.84% | 38 |
|
|
2023
Q1 | $3.08M | Buy |
3,752
+319
| +9% | +$241K | 1.04% | 31 |
|
|
2022
Q4 | $2.48M | Sell |
3,433
-150
| -4% | -$111K | 0.89% | 41 |
|
|
2022
Q3 | $2.47M | Sell |
3,583
-250
| -7% | -$157K | 0.92% | 34 |
|
|
2022
Q2 | $2.27M | Sell |
3,833
-160
| -4% | -$104K | 0.78% | 41 |
|
|
2022
Q1 | $2.79M | Sell |
3,993
-180
| -4% | -$114K | 0.79% | 39 |
|
|
2021
Q4 | $2.63M | Sell |
4,173
-36
| -0.9% | -$22.1K | 0.74% | 46 |
|
|
2021
Q3 | $2.55M | Buy |
4,209
+11
| +0.3% | +$6.83K | 0.76% | 41 |
|
|
2021
Q2 | $2.35M | Buy |
4,198
+295
| +8% | +$149K | 0.69% | 45 |
|
|
2021
Q1 | $1.85M | Buy |
3,903
+3,875
| +13,839% | +$1.89M | 0.6% | 58 |
|
|
2020
Q4 | $14K | Sell |
28
-100
| -78% | -$54K | ﹤0.01% | 336 |
|
|
2020
Q3 | $72K | Sell |
128
-900
| -88% | -$546K | 0.03% | 191 |
|
|
2020
Q2 | $641K | Hold |
1,028
| – | – | 0.27% | 84 |
|
|
2020
Q1 | $501K | Buy |
1,028
+1,000
| +3,571% | +$412K | 0.26% | 81 |
|
|
2019
Q4 | $10K | Sell |
28
-300
| -91% | -$101K | ﹤0.01% | 338 |
|
|
2019
Q3 | $91K | Sell |
328
-50
| -13% | -$14.8K | 0.05% | 157 |
|
|
2019
Q2 | $118K | Hold |
378
| – | – | 0.06% | 144 |
|
|
2019
Q1 | $155K | Hold |
378
| – | – | 0.08% | 127 |
|
|
2018
Q4 | $141K | Hold |
378
| – | – | 0.08% | 125 |
|
|
2018
Q3 | $153K | Hold |
378
| – | – | 0.08% | 130 |
|
|
2018
Q2 | $130K | Hold |
378
| – | – | 0.08% | 128 |
|
|
2018
Q1 | $130K | Hold |
378
| – | – | 0.08% | 124 |
|
|
2017
Q4 | $142K | Buy |
378
+100
| +36% | +$40.5K | 0.09% | 122 |
|
|
2017
Q3 | $124K | Hold |
278
| – | – | 0.08% | 124 |
|
|
2017
Q2 | $137K | Buy |
278
+28
| +11% | +$12.3K | 0.09% | 119 |
|
|
2017
Q1 | $97K | Hold |
250
| – | – | 0.07% | 128 |
|
|
2016
Q4 | $92K | Buy |
+250
| New | +$95.1K | 0.07% | 121 |
|
Other funds holding REGN
MCI
Sterling Investment Advisors (Pennsylvania)'s REGN Position: Q2 2026 in Review
Sterling Investment Advisors (Pennsylvania) reduced its Regeneron Pharmaceuticals (REGN) stake by 5.6% in Q2 2026, selling an estimated $119K and leaving 2,947 shares worth $1.84M. The position accounts for 0.31% of the portfolio, ranked #81.
Sterling Investment Advisors (Pennsylvania) first reported a position in REGN in Q4 2016 and has held it in 39 quarters since. The position peaked at $3.5M in Q2 2024. 518 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Sterling Investment Advisors (Pennsylvania) held 2,947 shares of Regeneron Pharmaceuticals worth $1.84M as of Q2 2026.
- Sterling Investment Advisors (Pennsylvania) sold 175 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $119K.
- Regeneron Pharmaceuticals made up 0.31% of Sterling Investment Advisors (Pennsylvania)'s portfolio in Q2 2026, its #81 holding.
- Sterling Investment Advisors (Pennsylvania) first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
- Sterling Investment Advisors (Pennsylvania)'s Regeneron Pharmaceuticals position peaked at $3.5M in Q2 2024.
- 518 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Sterling Investment Advisors (Pennsylvania)'s 13F filing for Q2 2026, filed 28 Jul 2026.